News | Heart Failure | July 07, 2023

CMS Establishes HCPCS code for Ultromics EchoGo Heart Failure

This helps to accelerate access to precision HFpEF detection

HCPCS code C9786 can now be used for billing artificial intelligence to aid the detection of Heart Failure with Preserved Ejection Fraction (HFpEF).

HCPCS code C9786 can now be used for billing artificial intelligence to aid the detection of Heart Failure with Preserved Ejection Fraction (HFpEF).


July 7, 2023 — Ultromics, a leading health technology company advancing a novel approach for detecting heart failure and its phenotypes, announced today the assignment of a new outpatient code by the Centers for Medicare and Medicaid Services (CMS), for its flagship product, EchoGo Heart Failure. 

CMS established a new HCPCS code (C9786) in the Hospital Outpatient Prospective Payment System (OPPS) for Ultromics' technology with the following descriptor "Echocardiography image post processing for computer aided detection of Heart Failure with Preserved Ejection Fraction, including interpretation and report," designated for Medicare beneficiaries receiving the service in the hospital outpatient setting. The new HCPCS code went into effect on July 1st, 2023. 

EchoGo Heart Failure is the first US Food and Drug Administration (FDA) cleared platform for detecting Heart Failure with Preserved Ejection Fraction (HFpEF), using a single view of an echocardiogram. The platform has the potential to catch disease earlier and get more patients on the pathway to treatment. 

CMS's position is supported by clinical evidence presented at the American Society of Echocardiography (ASE) 2023 Scientific Sessions, demonstrating the effectiveness of EchoGo Heart Failure for the detection of HFpEF. Combined with clearance and Breakthrough Device Designation by the FDA, providers can have trust and confidence in Ultromics' ability to deliver effective and innovative solutions for heart failure care. 

"This is a major milestone and will enable hospitals to accelerate the adoption of EchoGo Heart Failure, to improve detection of HFpEF within their systems" said Dr. Ross Upton, CEO and Founder of Ultromics. "Given the prevalence of HFpEF, this is a significant development toward recognizing and detecting a heavily underdiagnosed condition." 

As many as 50 percent of heart failure cases in the United States are HFpEF.1 Patients with HFpEF are difficult to identify, and greater awareness of the condition and clearer diagnostic pathways are needed.2 According to a JACC Scientific Statement on HFpEF, up to 64% of patients go undiagnosed.2 

EchoGo Heart Failure is an AI-enabled device that automatically analyses patient scans from a minimally invasive echocardiogram. It contains an AI algorithm, that once activated, screens for HFpEF. The technology can automate the detection process for a complex clinical syndrome where diagnosis is often uncertain, resulting in more patients getting a correct and expeditious diagnosis. 

The assigned HCPCS code (C9786) brings Ultromics one step closer to transforming cardiovascular care and solidifying its position as a leader in the field. With these codes in place, it opens the door for the adoption of EchoGo Heart Failure to empower healthcare providers with cutting-edge technology and the potential to improve patient outcomes. 

EchoGo Heart Failure received FDA clearance in the USA in December 2022. The device is available in the United States. 

Providers interested in using EchoGo Heart Failure may register their interest using on the Ultromics website at https://www.ultromics.com/products/echogo-heart-failure.


Related Content

News | Cardiac Imaging

November 16, 2023 — Cardiovascular diseases rank among the top causes of death across the world, and cardiac ...

Home November 16, 2023
Home
News | Cardiac Imaging

September 21, 2023 — Declines in cardiovascular procedure volumes observed early in the COVID-19 pandemic greatly ...

Home September 21, 2023
Home
News | Cardiac Imaging

July 11, 2023 — Hyperfine, Inc., the groundbreaking medical device company that created the Swoop system, the world’s ...

Home July 11, 2023
Home
Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

Home July 10, 2023
Home
News | Cardiac Imaging

June 29, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home June 29, 2023
Home
News | Cardiac Imaging

June 26, 2023 — Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited ...

Home June 26, 2023
Home
News | Cardiac Imaging

June 15, 2023 — Dr. Jonathan Weinsaft, an esteemed physician-scientist who focuses on clinical research and ...

Home June 15, 2023
Home
News | Cardiac Imaging

June 9, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home June 09, 2023
Home
Feature | Cardiac Imaging | By Mohammad Sahebjalal, MD

Invented in 1896 by Enrico Salvioni, the fluoroscope remains a flagship technology of modern medicine. The live video X ...

Home May 04, 2023
Home
News | Cardiac Imaging

April 26, 2023 — In the majority of cases, graft failure after heart transplantation is attributable to abnormalities ...

Home April 26, 2023
Home
Subscribe Now